|
Merck and Co Inc (NYSE: MRK) |
|
Price: $147.5300
$-0.93 
-0.626%
|
| Day's High:
| $149.41000366210938
| Week Perf:
| -2.71 %
|
| Day's Low: |
$ 147.18 |
30 Day Perf: |
12.69 % |
| Volume (M): |
6,611,268 |
52 Wk High: |
$ 156.92 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$112.20 |
| Open: |
$148.96 |
52 Wk Low: |
$77.58 |
|
|
| Market Capitalization (Millions $) |
364,399 |
| Shares
Outstanding (Millions) |
2,470 |
| Employees |
75,000 |
| Revenues (TTM) (Millions $) |
66,569 |
| Net Income (TTM) (Millions $) |
3,170 |
| Cash Flow (TTM) (Millions $) |
-2,675 |
| Capital Exp. (TTM) (Millions $) |
3,904 |
Business Description
Merck & Co. Inc. is a leading global pharmaceutical company that focuses on the research, development, manufacturing, and marketing of a wide array of innovative healthcare products. Operating in both human and animal health sectors, Merck aims to enhance health outcomes through its diverse portfolio, which includes prescription medications, vaccines, biologic therapies, and animal health products.
The company primarily distributes its products to various stakeholders in the healthcare sector, including drug wholesalers and retailers, hospitals, clinics, government agencies, and managed healthcare providers. Merck employs a team of professional representatives who engage with healthcare professionals, emphasizing the effectiveness, safety, and value of its offerings.
Merck has a strong commitment to scientific research and innovation, which has led to the development of numerous breakthrough therapies and vaccines. The company is actively involved in collaborations and partnerships that expand its ability to bring new treatments to market. This includes working with academic institutions, biotechnology companies, and government organizations to advance medical science.
In recent years, Merck has gained significant attention for its contributions to the development of vaccines and treatments for infectious diseases, including its work on the COVID-19 pandemic. The companys focus on oncology, vaccines, and animal health reflects its strategy to address some of the most pressing health issues globally.
Company Address: 126 East Lincoln Avenue Rahway 7065 NJ
Company Phone Number: 740-4000 Stock Exchange / Ticker: NYSE MRK
|
|
| Business Update
Published Wed, Oct 29 2025 12:11 PM UTC
European Commission Approves KEYTRUDA as Neoadjuvant and Adjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma Amidst Evolving Financial Landscape for Merck & Co., Inc.In an important stride for cancer treatment innovation, the European Commission (EC) has officially approved KEYTRUDA (pembrolizumab), developed by Merck & Co., known as MSD outside of t...
|
| Business Update
Published Mon, Oct 20 2025 8:21 AM UTC
Transformative Advances in Bladder Cancer Treatment against a Backdrop of Financial Shifts for Merck In the rapidly evolving landscape of pharmaceutical innovations, Merck & Co., known as MSD outside the United States and Canada, has unveiled promising clinical trial results that could redefine treatment strategies for muscle-invasive bladder cancer (MIBC). The incorporation...
|
| Business Update
Published Mon, Sep 22 2025 2:49 AM UTC
Exploring the FDA Approval of KEYTRUDA QLEX: A New Avenue for Solid Tumor Treatment and Its Implications for Merck & Co., Inc. In a significant advancement in cancer therapy, the U.S. Food and Drug Administration (FDA) has officially approved KEYTRUDA QLEX, a novel formulation combining pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous use. Manufactured by Merck...
|
| Business Update
Published Sat, Sep 20 2025 1:16 AM UTC
: Merck & Co., Inc. has received U.S. Food and Drug Administration (FDA) approval for its new subcutaneous formulation of KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph). This innovative therapy aims to improve convenience and accessibility for adult patients with solid tumors. However, concurrently, Merck is facing significant financial pressures, with risin...
|
| Business Update
Published Fri, Jun 13 2025 11:50 AM UTC
AbstractThe recent approvals of KEYTRUDA (pembrolizumab) signify a substantial advancement in the treatment landscape for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). Merck s collaborations further bolster its commitment to innovating therapeutic interventions across multiple oncological pathways. This article outlines key developmen...
|
| |
| U S |
|
 55.45 % |
of total Revenue |
| Non-US |
|
43.65 % |
of total Revenue |
| Pharmaceutical |
|
88.11 % |
of total Revenue |
| Animal Health |
|
11 % |
of total Revenue |
| U S Pharmaceutical |
|
52.27 % |
of total Revenue |
| U S Animal Health |
|
3.19 % |
of total Revenue |
| Non-US Pharmaceutical |
|
35.84 % |
of total Revenue |
| Non-US Animal Health |
|
7.81 % |
of total Revenue |
| Keytruda Pharmaceutical |
|
48.54 % |
of total Revenue |
| Keytruda U S Pharmaceutical |
|
28.24 % |
of total Revenue |
| Keytruda Non-US Pharmaceutical |
|
20.31 % |
of total Revenue |
| Keytruda Qlex Pharmaceutical |
|
0.79 % |
of total Revenue |
| Keytruda Qlex U S Pharmaceutical |
|
0.65 % |
of total Revenue |
| Keytruda Qlex Non-US Pharmaceutical |
|
0.13 % |
of total Revenue |
| Alliance revenue - Lynparza Pharmaceutical |
|
2.09 % |
of total Revenue |
| Alliance revenue - Lynparza U S Pharmaceutical |
|
0.91 % |
of total Revenue |
| Alliance revenue - Lynparza Non-US Pharmaceutical |
|
1.18 % |
of total Revenue |
| Alliance revenue - Lenvima Pharmaceutical |
|
1.57 % |
of total Revenue |
| Alliance revenue - Lenvima U S Pharmaceutical |
|
1.08 % |
of total Revenue |
| Alliance revenue - Lenvima Non-US Pharmaceutical |
|
0.49 % |
of total Revenue |
| Welireg Pharmaceutical |
|
1.22 % |
of total Revenue |
| Welireg U S Pharmaceutical |
|
0.93 % |
of total Revenue |
| Welireg Non-US Pharmaceutical |
|
0.29 % |
of total Revenue |
| Alliance Revenue - Reblozyl Pharmaceutical |
|
0.91 % |
of total Revenue |
| Alliance Revenue - Reblozyl U S Pharmaceutical |
|
0.79 % |
of total Revenue |
| Alliance Revenue - Reblozyl Non-US Pharmaceutical |
|
0.12 % |
of total Revenue |
| Gardasil Gardasil 9 Pharmaceutical |
|
6.56 % |
of total Revenue |
| Gardasil Gardasil 9 U S Pharmaceutical |
|
2.98 % |
of total Revenue |
| Gardasil Gardasil 9 Non-US Pharmaceutical |
|
3.59 % |
of total Revenue |
| ProQuad M-M-R II Varivax Pharmaceutical |
|
3.3 % |
of total Revenue |
| ProQuad M-M-R II Varivax U S Pharmaceutical |
|
2.51 % |
of total Revenue |
| ProQuad M-M-R II Varivax Non-US Pharmaceutical |
|
0.79 % |
of total Revenue |
| RotaTeq Pharmaceutical |
|
1.26 % |
of total Revenue |
| RotaTeq U S Pharmaceutical |
|
1.01 % |
of total Revenue |
| RotaTeq Non-US Pharmaceutical |
|
0.26 % |
of total Revenue |
| Vaxneuvance Pharmaceutical |
|
1.24 % |
of total Revenue |
| Vaxneuvance U S Pharmaceutical |
|
0.76 % |
of total Revenue |
| Vaxneuvance Non-US Pharmaceutical |
|
0.48 % |
of total Revenue |
| Capvaxive Pharmaceutical |
|
0.87 % |
of total Revenue |
| Capvaxive U S Pharmaceutical |
|
0.72 % |
of total Revenue |
| Capvaxive Non-US Pharmaceutical |
|
0.14 % |
of total Revenue |
| Winrevair Pharmaceutical |
|
3.22 % |
of total Revenue |
| Winrevair U S Pharmaceutical |
|
2.93 % |
of total Revenue |
| Winrevair Non-US Pharmaceutical |
|
0.29 % |
of total Revenue |
| Ohtuvayre Pharmaceutical |
|
0.8 % |
of total Revenue |
| Ohtuvayre U S Pharmaceutical |
|
0.8 % |
of total Revenue |
| Alliance revenue - Adempas Verquvo Pharmaceutical |
|
0.67 % |
of total Revenue |
| Alliance revenue - Adempas Verquvo U S Pharmaceutical |
|
0.67 % |
of total Revenue |
| Adempas Pharmaceutical |
|
0.48 % |
of total Revenue |
| Adempas Non-US Pharmaceutical |
|
0.48 % |
of total Revenue |
| Bridion Pharmaceutical |
|
2.9 % |
of total Revenue |
| Bridion U S Pharmaceutical |
|
2.62 % |
of total Revenue |
| Bridion Non-US Pharmaceutical |
|
0.28 % |
of total Revenue |
| Prevymis Pharmaceutical |
|
1.67 % |
of total Revenue |
| Prevymis U S Pharmaceutical |
|
0.83 % |
of total Revenue |
| Prevymis Non-US Pharmaceutical |
|
0.85 % |
of total Revenue |
| Zerbaxa Pharmaceutical |
|
0.5 % |
of total Revenue |
| Zerbaxa U S Pharmaceutical |
|
0.32 % |
of total Revenue |
| Zerbaxa Non-US Pharmaceutical |
|
0.18 % |
of total Revenue |
| Delstrigo Pharmaceutical |
|
0.46 % |
of total Revenue |
| Delstrigo U S Pharmaceutical |
|
0.06 % |
of total Revenue |
| Delstrigo Non-US Pharmaceutical |
|
0.4 % |
of total Revenue |
| Isentress Isentress HD Pharmaceutical |
|
0.36 % |
of total Revenue |
| Isentress Isentress HD U S Pharmaceutical |
|
0.21 % |
of total Revenue |
| Isentress Isentress HD Non-US Pharmaceutical |
|
0.15 % |
of total Revenue |
| Dificid Pharmaceutical |
|
0.21 % |
of total Revenue |
| Dificid U S Pharmaceutical |
|
0.15 % |
of total Revenue |
| Dificid Non-US Pharmaceutical |
|
0.06 % |
of total Revenue |
| Lagevrio Pharmaceutical |
|
0.17 % |
of total Revenue |
| Lagevrio U S Pharmaceutical |
|
0.1 % |
of total Revenue |
| Lagevrio Non-US Pharmaceutical |
|
0.07 % |
of total Revenue |
| Januvia Pharmaceutical |
|
2.25 % |
of total Revenue |
| Januvia U S Pharmaceutical |
|
1.55 % |
of total Revenue |
| Januvia Non-US Pharmaceutical |
|
0.71 % |
of total Revenue |
| Janumet Pharmaceutical |
|
1.27 % |
of total Revenue |
| Janumet U S Pharmaceutical |
|
0.42 % |
of total Revenue |
| Janumet Non-US Pharmaceutical |
|
0.85 % |
of total Revenue |
| Other pharmaceutical Pharmaceutical |
|
4.76 % |
of total Revenue |
| Other pharmaceutical U S Pharmaceutical |
|
1.02 % |
of total Revenue |
| Other pharmaceutical Non-US Pharmaceutical |
|
3.73 % |
of total Revenue |
| Livestock Animal Health |
|
6.53 % |
of total Revenue |
| Livestock U S Animal Health |
|
1.3 % |
of total Revenue |
| Livestock Non-US Animal Health |
|
5.24 % |
of total Revenue |
| Companion Animal Animal Health |
|
4.46 % |
of total Revenue |
| Companion Animal U S Animal Health |
|
1.89 % |
of total Revenue |
| Companion Animal Non-US Animal Health |
|
2.57 % |
of total Revenue |
| Alliance revenue - Koselugo Pharmaceutical |
|
0.99 % |
of total Revenue |
| Corporate Non-Segment |
|
0.9 % |
of total Revenue |
| Corporate Non-U S |
|
0.82 % |
of total Revenue |
| Corporate Non-Non-US |
|
0.08 % |
of total Revenue |
| United States |
|
56.27 % |
of total Revenue |
| Europe Middle East and Africa |
|
23.86 % |
of total Revenue |
| Latin America |
|
5.37 % |
of total Revenue |
| Asia Pacific other than China and Japan |
|
4.53 % |
of total Revenue |
| Japan |
|
3.41 % |
of total Revenue |
| China |
|
2.39 % |
of total Revenue |
| Other |
|
4.17 % |
of total Revenue |
| Total profits |
|
99.1 % |
of total Revenue |
| Total profits Pharma- ceutical |
|
88.11 % |
of total Revenue |
| Total profits Animal Health |
|
11 % |
of total Revenue |
| Other profits |
|
0.9 % |
of total Revenue |
1.82%